Markers of drug resistance in relapsing colon cancer
- Cite this article as:
- Lazaris, A., Kavantzas, N., Zorzos, H. et al. J Cancer Res Clin Oncol (2002) 128: 114. doi:10.1007/s00432-001-0310-5
- 64 Downloads
Purpose: 5-Fluorouracil failure and drug resistance, which often occurs during chemotherapy, is still a great obstacle to the success of human colon cancer treatment. Thus, the comparative study of markers of drug resistance in cancer cells before and after chemotherapy may be extremely helpful in the selection of the appropriate chemotherapeutic drug in colon cancer patients who fail adjuvant treatment with 5-fluorouracil. In the present study we examined the differential expression of three multidrug resistance-related proteins (i.e., P-glycoprotein, MRP, and LRP) and of topoisomerase IIα in a series of 20 primary colon carcinomas and their recurrences. Methods: All markers were determined at tissue level by three-step immunohistochemistry using appropriate monoclonal antibodies, and the markers' immunopositivity was quantified by image analysis. In addition, Feulgen stain was used for the assessment of nuclear DNA content of malignant cells at their primary location. Results: Some degree of aneuploidy was detected in all primary carcinomas. The immunoexpression of the three multidrug resistance-related proteins did not change significantly, either qualitatively (positivity vs negativity) or quantitatively, after chemotherapy. On the contrary, the percentages of topoisomerase IIα-positive malignant cells were significantly increased in the tumour recurrences by comparison to their primary locations (P=0.011). Conclusions: According to our results, increased topoisomerase IIα immunohistochemical expression appears to be part of the malignant cells' phenotype in recurrent colon cancers. Therapeutic options after failure of 5-fluorouracil-based treatment could therefore include appropriate topoisomerase IIα-targeted drugs.